ClinicalTrials.gg
Not yet recruitingNCT07348991Updated Feb 10, 2026

Predicting Severe Cardiac Arrhythmias in the Perioperative Period Using AI-ECG

An observational study in Atrial Fibrillation, Atrioventricular Block, Second and Third Degree and Sinus Node Dysfunction, sponsored by I.M. Sechenov First Moscow State Medical University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by I.M. Sechenov First Moscow State Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

During the preoperative examination, in addition to the standard examination recommended before high-risk cardiac surgeries, a digital single-lead ECG is recorded using portable CardioQUARK devices. This ECG is analyzed for time, amplitude, and frequency parameters-more than 200 parameters per cardiac cycle. Additionally, the available parameters of a standard 12-lead ECG recording are determined. All parameters of both single-lead and 12-lead ECGs will be included in a multivariate regression analysis to determine the optimal method for predicting atrial fibrillation, life-threatening cardiac arrhythmias, and conduction abnormalities in the perioperative period after high-risk cardiac procedures.

The study will include patients undergoing high-risk cardiac surgeries, such as those on the heart, aorta, esophagus, pancreas, liver, and lungs, as well as high-risk oncological surgeries. A partial analysis will also be performed depending on the type of intervention. Rhythm and conduction disturbances will be recorded during surgery, as well as in the postoperative period, using ECG monitors, 24-hour ECG monitoring, and repeated recordings of a standard ECG when complaints or signs of unstable hemodynamics arise

Read the detailed description

In study, the investigators plan to identify single-channel and 12-lead ECG parameters that correlate significantly with the occurrence of atrial fibrillation and life-threatening cardiac arrhythmias and conduction disturbances in the perioperative period after high-risk cardiac interventions.

A prospective, non-randomized, observational, controlled, single-center study consisting of two consecutive stages is being conducted.

The first stage involves identifying single-channel and 12-lead ECG parameters that correlate significantly with the onset of atrial fibrillation and life-threatening cardiac arrhythmias and conduction disorders in the perioperative period after interventions with high cardiac risk. Participants who meet the inclusion criteria will undergo the following during preoperative preparation: recording of a digital single-channel ECG using the CardioQVARK software and hardware complex (CardioQVARK medical device (Electrocardiograph) issued by Roszdravnadzor (Federal Service for Surveillance in Healthcare) P3H 2024/22855, issued on June 5, 2024); a digital 12-lead ECG; an extended echocardiographic examination; and 24-hour Holter ECG monitoring.

The single-channel ECG will be recorded for 3 minutes at rest in a sitting position. The participants leans back against the back of the chair, legs uncrossed, arms resting on the knees or on the table. Standard lead I is recorded using the CardioQVARK software and hardware complex.

Next, the parameters of single-channel and 12-channel ECG are identified that have a reliable correlation with the occurrence of atrial fibrillation and life-threatening arrhythmias and conduction disorders in the perioperative period after interventions with high cardiac risk, followed by the creation of a machine learning model and/or or neural network analysis with deep learning support for predicting the occurrence of atrial fibrillation and life-threatening arrhythmias and conduction disorders.

The second stage will involve testing using a test sample of the algorithm, taking into account the ECG parameters which, according to the statistical analysis performed in the first stage, had the highest sensitivity and specificity in predicting the onset of atrial fibrillation and life-threatening cardiac arrhythmias and conductions disorders.

02

Conditions studied

  • Atrial Fibrillation
  • Atrioventricular Block, Second and Third Degree
  • Sinus Node Dysfunction
  • Ventricular Tachycardia (VT)
  • Ventricular Fibrillation

Keywords

  • Electrocardiogram
  • Artificial intelligence
  • Cardiac arrhythmias
  • Atrioventricular block
  • Perioperative
  • Atrial fibrillation
03

In context

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

This study's planned enrollment of 300 is close to the median of 300 across 1,400 observational studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

I.M. Sechenov First Moscow State Medical University is the lead sponsor of 137 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will analyze patients undergoing elective high-risk cardiac surgeries, including cardiac surgery, aortic surgery, esophageal and gastric cardia surgery, and thoracic surgery. Patients undergoing large-scale oncological surgeries will also be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age;
  • Scheduled surgery with high cardiac risk
  • was given to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Cancellation of the surgery for any reason;
  • The patient's unwillingness to continue participating in the study;
  • Poor quality of the recording on a single-channel ECG monitor.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • intervention group

    patients meeting the inclusion criteria who are hospitalised for surgery with a high cardiovascular risk

    Diagnostic Test: digital single-channel ECG recording

Interventions

  • Diagnostic testdigital single-channel ECG recording

    A single-channel ECG will be recorded for 3 minutes while the patient is sitting at rest. The patient leans back against the chair, legs uncrossed, and arms resting on the knees or on the table. Standard lead I is recorded using the CardioQVARK software and hardware complex (CardioQVARK medical device (Electrocardiograph) issued by Roszdravnadzor (Federal Service for Surveillance in Healthcare) P3H 2024/22855, issued on June 5, 2024).

06

What researchers measure

Primary outcomes

  1. specificity, sensitivity, prognostic significance of a positive and negative result, diagnostic accuracy

    statistical parameter of diagnostic and prognostic accuracy of the method under study

    Time frame: 30 days after sugery starts

  2. specificity, sensitivity, prognostic significance of a positive and negative result, prognostic significance of a positive and positive result, diagnostic accuracy

    statistical parameter of diagnostic and prognostic accuracy of the method under study

    Time frame: perioperative period - from the surgery starts till 30 days after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Paroxysms of atrial fibrillation during planned cardiac surgery under artificial circulation / E. P. Gulyaeva-Seltsovskaya, I. Dkhif, A. A. Mols [et al.] // Bulletin of the Smolensk State Medical Academy. - 2023. - Vol. 22, No. 4. - P. 100-106. - DOI 10.37903/vsgma.2023.4.14. - EDN MIIWSU
  • Chomakhidze P.Sh., Kurbanalieva N.K., Nebezhev A.A., Sedov V.P., Syrkin A.L. Modern aspects of preoperative examination in planned extracardiac interventions. Consilium Medicum. 2025;27(1): DOI: 10.26442/20751753.2025.1.203060 © CONSILIUM MEDICUM LLC, 2025

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Clinical study report

Time frame: 01.2026-01.2028

Access criteria: email call

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07348991
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

Peter Chomakhidze, Prof.
Contact
chomakhidze_p_sh@staff.sechenov.ru
+79166740369
Ivan Kuznetsov, Dr.
Contact
ivankuz1310@gmail.com
+79688487558

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion